Journal Article Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design

Ako, Junya  ,  Hibi, Kiyoshi  ,  Kozuma, Ken  ,  Miyauchi, Katsumi  ,  Morino, Yoshihiro  ,  Shinke, Toshiro  ,  Tsujita, Kenichi  ,  Uno, Kiyoko  ,  Kawabata, Yumiko  ,  Hiro, Takafumi

71 ( 43226 )  , pp.583 - 589 , 2018-06 , Elsevier B.V.
ISSN:0914508718764738
Description
Background: Serial intravascular ultrasound (IVUS) imaging can be used to evaluate the effect of cholesterol-lowering on coronary atheroma progression and plaque volume, with evidence of potential incremental effects with more aggressive lipid-lowering treatments. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9). This study will investigate the effect of alirocumab on coronary artery plaque volume in Japanese patients with a recent acute coronary syndrome (ACS) and hypercholesterolemia while on stable statin therapy. Methods: ODYSSEY J-IVUS is a phase IV, open-label, randomized, blinded IVUS analysis, parallel-group, multicenter study in Japanese adults recently hospitalized for an ACS and who have elevated low-density lipoprotein cholesterol (LDL-C) values [≥100 mg/dL (2.6 mmol/L)] at ACS diagnosis and suboptimal LDL-C control on stable statin therapy. Patients will be randomized (1:1) to receive alirocumab or standard-of-care (SOC). The alirocumab arm will receive alirocumab 75 mg every 2 weeks (Q2W) added to statin therapy (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day), with a dose increase to 150 mg Q2W in patients whose LDL-C value remains ≥100 mg/dL at week 12. The SOC arm will receive atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day, with dose adjustment to achieve LDL-C <100 mg/dL. Post-treatment IVUS imaging will be done at week 36 ± 2. The primary objective is to compare the effect of alirocumab versus SOC on coronary atheroma progression (percent change in normalized total atheroma volume) after 9 months of treatment. Conclusion: ODYSSEY J-IVUS will provide insights into the effect of alirocumab on coronary atherosclerotic plaque volume in patients with a recent ACS and hypercholesterolemia while on stable statin therapy.
Full-Text

http://www.lib.kobe-u.ac.jp/repository/90005010.pdf

Number of accesses :  

Other information